Selank: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no outcome described below should be read as a promise. Every dose, duration or effect stated on this page is attributed in the same sentence to the published paper that reported it.

Module 1 — What Selank Is and How It Has Been Studied

Definition and class

Selank is a synthetic heptapeptide belonging to the class of short regulatory peptides. It is described in the literature as a peptide analogue of tuftsin, an endogenous immunomodulatory tetrapeptide fragment, extended with a stabilising amino acid sequence at the C-terminus. Papers that characterise it pharmacologically group it with anxiolytic and nootropic peptides rather than with benzodiazepines or with classical small-molecule psychotropics, and one experimental paper explicitly frames it as "a peptide analog of tuftsin" when testing it against morphine withdrawal signs in rats (PMID 36322304).

Origin

Selank originated in Russian academic pharmacology, and essentially the entire clinical literature is Russian-language. Two of the clinical papers in this course appeared in Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, one describing efficacy and possible mechanisms of action of "a new peptide anxiolytic selank" in generalised anxiety disorders and neurasthenia (PMID 18454096), the other addressing optimisation of anxiety disorder treatment with selank (PMID 26356395). Preclinical work is dominated by the Bulletin of Experimental Biology and Medicine, with additional cell-culture and imaging work published in Frontiers in Pharmacology and Doklady Biological Sciences.

Forms and the "N-acetyl" designation

The name most often searched — N-acetyl Selank — refers to a chemically modified version in which the N-terminus carries an acetyl group, a common strategy for slowing enzymatic degradation of short peptides. It is important to be precise about what the verified literature supports: the studies summarised in this course investigated Selank, and none of them was framed as a head-to-head comparison of acetylated versus non-acetylated forms. Readers encountering N-acetyl Selank material should therefore treat published Selank findings as findings about Selank, not as validated data on an acetylated derivative.

Study types represented

• Cell culture: human IMR-32 neuroblastoma cells used to profile GABAergic gene expression (PMID 28293190).
• Ex vivo electrophysiology: rat hippocampal CA1 neurons (PMID 28361410).
• Rodent behavioural and organ-level models: chronic mild stress, foot-shock stress, restraint stress, social stress, ethanol-induced memory impairment and morphine withdrawal.
• Human clinical reports: two Russian psychiatry papers on anxiety disorders and neurasthenia.
• Neuroimaging methodology: a functional connectomic analysis of Selank and Semax effects (PMID 32342318).

Limits of the evidence in Module 1

The corpus is small, geographically concentrated, and heavily weighted toward short rodent experiments. Much of it is published in journals with limited English-language indexing of full methods. No verified paper in this course establishes equivalence between Selank and any acetylated analogue, and no verified paper describes manufacturing or purity standards for material circulating outside approved channels.

Module 2 — Mechanism as Described in the Literature

GABAergic gene expression

Two papers form the backbone of the GABA hypothesis. A 2016 study reported that Selank administration affected the expression of several genes involved in GABAergic neurotransmission (PMID 26924987). A follow-up in human IMR-32 neuroblastoma cells compared GABA, Selank and olanzapine and reported that all three altered the expression of genes involved in GABAergic neurotransmission in that cell line (PMID 28293190). Researchers used these transcriptional signatures to argue that Selank's anxiolytic profile may be mediated through modulation of the GABA system rather than through direct receptor agonism.

Synaptic activity

A 2017 electrophysiology study examined spontaneous synaptic activity in rat hippocampal CA1 neurons and reported that Selank modified that activity, providing a cellular-level observation consistent with the GABAergic gene-expression work (PMID 28361410).

Neurotrophic signalling

A 2019 rat study reported that Selank protected against ethanol-induced memory impairment and linked this to regulation of BDNF content in the hippocampus and prefrontal cortex (PMID 31625062). BDNF is therefore a second proposed mechanistic node alongside GABAergic signalling.

Immune and cytokine signalling

Because Selank derives from tuftsin, an immunoactive fragment, several groups examined immune readouts. A study conducted under "social" stress conditions reported an influence of Selank on cytokine levels (PMID 32621722). This line of work frames Selank as acting at the interface of stress physiology and immune signalling rather than purely as a CNS agent.

Network-level description

A 2020 paper applied a functional connectomic approach to studying the effects of Selank and Semax, moving the mechanistic question from single receptors to distributed network patterns (PMID 32342318).

Limits of the evidence in Module 2

Gene-expression changes in a neuroblastoma cell line are not proof of a receptor mechanism in an intact human brain. None of the verified papers identifies a specific high-affinity binding site for Selank, and the GABAergic, BDNF and cytokine findings have not been integrated into a single validated causal model. Mechanistic plausibility is not the same as demonstrated clinical mechanism.

Module 3 — Reported Outcomes by Study

Reading the rodent stress studies carefully

Three of the rodent papers are organ-level rather than behavioural. The liver morphology study in chronic foot-shock stress (PMID 31243679) and the hepatocyte functional-state study in restraint stress (PMID 28853100) both examined the liver of stressed animals. These are descriptive histological and functional characterisations, not safety trials, and they do not establish that any observed change would occur in humans.

The diazepam combination question

The chronic mild stress study is frequently cited because it examined Selank alongside an established anxiolytic, reporting that the peptide enhanced diazepam's anxiety-reducing effect in rats (PMID 28280289). An interaction observed in a rodent stress paradigm does not translate into any statement about combining substances in people, and the verified literature contains no human interaction trial.

Limits of the evidence in Module 3

Sample sizes, blinding and control conditions are not recoverable from abstract-level information for most of these papers. The two human papers are Russian-language clinical reports rather than large multicentre randomised trials, and no verified paper in this set reports long-term follow-up, replication by an independent group outside the originating research tradition, or a registered outcome measure in an international trial registry.

Module 4 — Selank Side Effects: What Studies Report

Adverse-event reporting is the weakest part of the Selank literature, and this module states only what the verified papers contain.

The clinical paper on generalised anxiety disorders and neurasthenia framed selank as a peptide anxiolytic and discussed its efficacy and possible mechanisms, and tolerability discussion in this literature is typically presented in the context of comparison with classical anxiolytics rather than as a systematic adverse-event table (PMID 18454096). The second clinical paper addressed optimisation of anxiety disorder treatment with selank, again within a treatment-practice framing rather than a dedicated safety study (PMID 26356395).

Organ-level signals come from the stress studies. Researchers examined morphological parameters of rat liver in chronic foot-shock stress with Selank administration (PMID 31243679), and a separate study examined the functional state of rat hepatocytes under restraint stress (PMID 28853100). These papers indicate that hepatic tissue was considered a relevant endpoint by investigators, which is itself informative about where researchers looked for effects. Immune endpoints were addressed by the cytokine study under social stress (PMID 32621722); because Selank derives from an immunoactive peptide fragment, changes in cytokine signalling are a mechanistically expected domain to monitor.

What cannot be said: the verified literature does not contain a pooled safety analysis, a dose-limiting toxicity study, a pregnancy or paediatric safety dataset, a drug-interaction study in humans, or post-marketing surveillance data suitable for estimating adverse-event frequencies.

Limits of the evidence in Module 4

Absence of reported adverse events in small short-duration studies is not evidence of safety. Rodent organ studies conducted under severe stress paradigms cannot be extrapolated to human tolerability, and no verified paper here provides an incidence rate for any specific adverse event.

Module 5 — Pharmacokinetics Where Data Exist

This module is deliberately short, because the verified paper set does not include a dedicated human pharmacokinetic study. No paper in this course reports plasma half-life, bioavailability by any route, volume of distribution, metabolite identification or clearance values for Selank or for an acetylated analogue.

What can be said from the available work is indirect. The peptide is described as a tuftsin analogue engineered with a stabilising C-terminal extension, and this design rationale — reducing rapid peptidase degradation of a very short native fragment — is the standard justification given in papers that identify Selank as a peptide analogue of tuftsin (PMID 36322304). Central effects observed in rodents, such as changes in hippocampal CA1 spontaneous synaptic activity (PMID 28361410) and altered BDNF content in the hippocampus and prefrontal cortex (PMID 31625062), imply that some pharmacologically relevant signal reached or acted upon central tissue in those experimental conditions, but the studies were not designed to quantify exposure.

Limits of the evidence in Module 5

Any half-life figure, intranasal bioavailability percentage or duration-of-action claim circulating in secondary sources is not supported by the verified papers listed here. Readers should treat such numbers as unsourced unless a primary pharmacokinetic publication is produced.

Module 6 — Regulatory Status, Stated Factually

Selank has not been approved as a drug by the United States Food and Drug Administration, and it is not the active ingredient in any FDA-approved product. It is not an approved medicine in the European Union under a centralised marketing authorisation. Its clinical development and clinical use occurred within Russian medical practice, which is why the human literature in this course consists of Russian-language psychiatry papers on anxiety disorders and neurasthenia (PMID 18454096, PMID 26356395).

In the United States, material sold under the names Selank or N-acetyl Selank is generally labelled research use only (RUO). RUO labelling means the material is not intended for diagnostic or therapeutic use in humans or animals, and it carries no assurance of pharmaceutical-grade purity, sterility or identity verification. Selank is also not a dietary supplement ingredient: peptides of this type do not meet the statutory definition, and marketing them as supplements has been a recurring subject of regulatory attention.

Regarding compounding, US compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may generally compound only from bulk substances that meet specific statutory criteria, such as appearing in an applicable USP or NF monograph, being a component of an approved drug, or appearing on the relevant FDA bulk drug substances list. Substances that do not satisfy those criteria are not eligible for compounding. Peptides lacking approved-drug status and monograph coverage are therefore in a constrained position.

Finally, Selank is not listed as an approved therapeutic in most national formularies outside Russia, and its status in sport is governed by anti-doping authorities' own listings rather than by drug-approval agencies. This page describes regulatory facts for educational purposes and is not legal advice; regulatory status changes and varies by jurisdiction.

Limits of the evidence in Module 6

Regulatory classification reflects administrative and legal processes, not scientific verdicts. A compound may be unapproved because no sponsor pursued approval in a given market rather than because it failed trials — and equally, absence of approval means no regulator has independently reviewed efficacy and safety data for that market.

What the Studies Did Not Test

• Acetylated versus non-acetylated forms. No verified paper compared N-acetyl Selank with Selank on any endpoint.
• Long-term human use. The verified human papers concern anxiety disorders and neurasthenia treatment (PMID 26356395); none in this set reports multi-year follow-up.
• Healthy-volunteer cognitive enhancement. The rodent cognition work tested protection against ethanol-induced memory impairment, not enhancement in unimpaired subjects (PMID 31625062).
• Human pharmacokinetics. No exposure, half-life or bioavailability data appear in the verified set.
• Human drug interactions. The diazepam interaction was examined in rats under chronic mild stress (PMID 28280289), not in people.
• Opioid withdrawal in humans. Attenuation of aversive withdrawal signs was reported in rats (PMID 36322304).
• Systematic adverse-event frequency. No incidence data are available from the verified papers.

Readers evaluating Selank should hold two facts together: there is a coherent and internally consistent mechanistic literature spanning gene expression (PMID 26924987), cell culture (PMID 28293190) and network imaging (PMID 32342318), and there is an almost complete absence of the large, independent, registered human trials that regulators require. This page is for educational purposes only and is not medical advice; consult a licensed physician regarding any health question.

References

• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (Bulletin of Experimental Biology and Medicine, 2019)
• The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress (Current Reviews in Clinical and Experimental Pharmacology, 2021)
• Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (Bulletin of Experimental Biology and Medicine, 2022)
• Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress (Bulletin of Experimental Biology and Medicine, 2017)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (Frontiers in Pharmacology, 2017)
• Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Bulletin of Experimental Biology and Medicine, 2019)
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008)
• Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons (Bulletin of Experimental Biology and Medicine, 2017)
• Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission (Frontiers in Pharmacology, 2016)
• Optimization of the treatment of anxiety disorders with selank (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015)